Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Novel Agents with Efficacy Against Cellular Models of Familial Platelet Disorder with Myeloid Malignancy (FPD-MM) Associated with Germline Mutant RUNX1

Christopher Peter Mill, Warren C. Fiskus, Courtney D. DiNardo, Patrick K Reville, John Davis, Christine Birdwell, Kaberi Das, Hanxi Hou, Koichi Takahashi, Sanam Loghavi, Joseph D. Khoury, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 2765.

https://doi.org/10.1182/blood-2023-190655

Published: 2023

Journal Articles

Pre-Clinical Efficacy of CDK7 Inhibitor-Based Combinations in Cellular Models of Advanced Myeloproliferative Neoplasms (MPN) Transformed to AML

Warren C. Fiskus, Prithviraj Bose, Lucia Masarova, Christopher Peter Mill, Christine Birdwell, John Davis, Kaberi Das, Hanxi Hou, Taghi Manshouri, Kevin Philip, Noor Alhamadani, Alicia Matthews, Sanam Loghavi, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 1783.

https://doi.org/10.1182/blood-2023-185089

Published: 2023

Journal Articles

Notable Efficacy of Co-Treatment with FHD-286, a Dual BRG1/BRM ATP-Ase Inhibitor, and Menin or BET Inhibitor, Decitabine or Venetoclax Against AML with MLL-r or Mutant NPM1

Warren C. Fiskus, Jessica Piel, Murphy Hentemann, Christopher Peter Mill, Christine Birdwell, Kaberi Das, John Davis, Hanxi Hou, Noor Alhamadani, Kevin Philip, Alicia Matthews, Tapan M. Kadia, Naval Daver, Sanam Loghavi, Branko Cuglievan, Courtney D. DiNardo, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 4160.

https://doi.org/10.1182/blood-2023-182575

Published: 2023

Journal Articles

Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase

Warren C. Fiskus, Lucia Masarova, Christopher Peter Mill, Christine Birdwell, Kaberi Das, John Davis, Hanxi Hou, Noor Alhamadani, Kevin Philip, Alicia Matthews, Taghi Manshouri, Tapan M. Kadia, Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Sanam Loghavi, Marie Törngren, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 741.

https://doi.org/10.1182/blood-2023-185031

Published: 2023

Journal Articles

Actionable Findings from an Unbiased Drug Screen for Novel Single Agent and Combination Therapies Against AML with Mecom Re-Arrangement

Christine Birdwell, Warren C. Fiskus, Christopher Peter Mill, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Koji Sasaki, John Davis, Kaberi Das, Hanxi Hou, Michele Ceribelli, Kapil N. Bhalla

Blood (2023) 142 (Supplement 1): 1419.

https://doi.org/10.1182/blood-2023-188371

Published: 2023

Journal Articles

Pre-Clinical Efficacy of Targeting Baf Complexes through Inhibition of the Dual Atpases BRG1 and BRM By FHD-286 in Cellular Models of AML of Diverse Genetic Background

Warren C. Fiskus, Jessica Piel, Murphy Hentemann, Christopher Peter Mill, Christine E Birdwell, Kaberi Das, John A. Davis, Noor Alhamadani, Kevin Philip, Tapan M. Kadia, Naval Daver, Sanam Loghavi, Courtney D. DiNardo, Kapil N. Bhalla

Blood (2022) 140 (Supplement 1): 8819–8820.

https://doi.org/10.1182/blood-2022-164513

Published: 2022

Journal Articles

Preclinical Efficacy of Novel Drug Combination Against AML with 3q26 Lesions and EVI1 Overexpression

Christine E Birdwell, Warren C. Fiskus, Tapan M. Kadia, Christopher Peter Mill, John A. Davis, Kaberi Das, Naval Daver, Courtney D. DiNardo, Koichi Takahashi, Koji Sasaki, Stephen Horrigan, Kapil N. Bhalla

Blood (2022) 140 (Supplement 1): 493–494.

https://doi.org/10.1182/blood-2022-170715

Published: 2022

Journal Articles

Efficacy of Novel Non-Chemotherapy Combinations Against AML Cells with Mutant NPM1

Christopher Peter Mill, Warren C. Fiskus, John A. Davis, Kaberi Das, Christine E Birdwell, Tapan M. Kadia, Koji Sasaki, Koichi Takahashi, Courtney D. DiNardo, Sanam Loghavi, Naval Daver, Kapil N. Bhalla

Blood (2022) 140 (Supplement 1): 5860–5861.

https://doi.org/10.1182/blood-2022-169584

Published: 2022

Journal Articles

Bruton's Tyrosine Kinase (BTK) Degrader Nx-2127 Exhibits Lethal Activity and Synergy with Venetoclax and BET Protein Inhibitor Against MCL Cells Sensitive or Resistant to Covalent BTK Inhibitors

Warren C. Fiskus, Kaberi Das, Christopher Peter Mill, Christine E Birdwell, John A. Davis, Noor Alhamadani, Kevin Philip, May Tan, Robert A Brown, Michael R Green, Kapil N. Bhalla

Blood (2022) 140 (Supplement 1): 5980–5981.

https://doi.org/10.1182/blood-2022-168483

Published: 2022

Journal Articles

Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53

Warren C. Fiskus, Kaberi Das, Christopher Peter Mill, Christine E Birdwell, John A. Davis, Kevin Philip, Noor Alhamadani, Tapan M. Kadia, Naval Daver, Koji Sasaki, Koichi Takahashi, Sanam Loghavi, Courtney D. DiNardo, Jesse Vargas, Kapil N. Bhalla

Blood (2022) 140 (Supplement 1): 8807–8808.

https://doi.org/10.1182/blood-2022-165012

Published: 2022

Journal Articles

Clinical-Stage Menin Inhibitor KO-539 Is Synergistically Active with Multiple Classes of Targeted Agents in KMT2A-r and NPM1-Mutant AML Models

John A. Davis, Warren C. Fiskus, Naval Daver, Christopher Peter Mill, Christine Birdwell, Arnold Salazar, Kevin Philip, Tapan M. Kadia, Courtney D. DiNardo, Mollie Leoni, Francis Burrows, Kapil N. Bhalla

Blood (2021) 138 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2021-149831

Published: 2021

Journal Articles

Pre-Clinical Efficacy of Targeting TBL1/R-β-Catenin-TCF7L2 Axis Against AML with 3q26 Lesions and EVI1 Overexpression

Christine Birdwell, Warren C. Fiskus, Christopher Peter Mill, John A. Davis, Arnold Salazar, Courtney D. DiNardo, Koichi Takahashi, Steve Horrigan, Tapan M. Kadia, Kapil N. Bhalla

Blood (2021) 138 (Supplement 1): 3349.

https://doi.org/10.1182/blood-2021-154285

Published: 2021

Journal Articles

Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Blood (2021) 138 (Supplement 1): 3421.

https://doi.org/10.1182/blood-2021-154351

Published: 2021

Journal Articles

Preclinically Effective Menin Inhibitor SNDX-50469 and SNDX-5613-Based Combinations Against MLL1-Rearranged (MLL-r) or NPM1-Mutant AML Models

Warren C. Fiskus, Christopher Peter Mill, Christine Birdwell, John A. Davis, Arnold Salazar, Kevin Philip, Tapan M. Kadia, Courtney D. DiNardo, Koichi Takahashi, Gerard M. McGeehan, Naval Daver, Kapil N. Bhalla

Blood (2021) 138 (Supplement 1): 3340.

https://doi.org/10.1182/blood-2021-152060

Published: 2021

Journal Articles

Homoharringtonine and Mebendazole Are Preferentially Lethal Against Models of Myeloid Malignancy Associated with Germline Mutant RUNX1

Christopher Peter Mill, Warren C. Fiskus, Courtney D. DiNardo, Christine Birdwell, Arnold Salazar, Arnold Salazar, John A. Davis, Koichi Takahashi, Joseph D. Khoury, Kapil N. Bhalla

Blood (2021) 138 (Supplement 1): 1177.

https://doi.org/10.1182/blood-2021-152871

Published: 2021

Journal Articles

Targeting Levels, Aberrant Localization or Oligomerization of Mutant Nucleophosmin Induces Differentiation and Loss of Survival of Human AML Cells with Mutant NPM1.

Ramesh Balusu, Warren C. Fiskus, Rekha Rao, Kathleen M. Buckley, Yongchao Wang, Atul Joshi, Sanjay Koul, Anand Jillella, Celalettin Ustun, Susan Sunay, H. Jean Khoury, Kapil N. Bhalla

Blood (2009) 114 (22): 2656.

https://doi.org/10.1182/blood.V114.22.2656.2656

Published: 2009

Journal Articles

Synergistic Activity of Co-Treatment with PIM1 Kinase Inhibitor SGI-1776 and Histone Deacetylase Inhibitor Panobinostat or Heat Shock Protein 90 Inhibitor AUY922 against Human CML and Myeloproliferative Neoplasm (MPN) Cells.

Warren C. Fiskus, Kathleen M. Buckley, Rekha Rao, Yongchao Wang, Atul Joshi, Daniel G. Chong, Anand Jillella, Celalettin Ustun, Peter Atajada, Cornelia Quadt, Kapil N. Bhalla

Blood (2009) 114 (22): 2651.

https://doi.org/10.1182/blood.V114.22.2651.2651

Published: 2009

NARROW

Novel Agents with Efficacy Against Cellular Models of Familial Platelet Disorder with Myeloid Malignancy (FPD-MM) Associated with Germline Mutant RUNX1

Pre-Clinical Efficacy of CDK7 Inhibitor-Based Combinations in Cellular Models of Advanced Myeloproliferative Neoplasms (MPN) Transformed to AML

Notable Efficacy of Co-Treatment with FHD-286, a Dual BRG1/BRM ATP-Ase Inhibitor, and Menin or BET Inhibitor, Decitabine or Venetoclax Against AML with MLL-r or Mutant NPM1

Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase

Actionable Findings from an Unbiased Drug Screen for Novel Single Agent and Combination Therapies Against AML with Mecom Re-Arrangement

Pre-Clinical Efficacy of Targeting Baf Complexes through Inhibition of the Dual Atpases BRG1 and BRM By FHD-286 in Cellular Models of AML of Diverse Genetic Background

Preclinical Efficacy of Novel Drug Combination Against AML with 3q26 Lesions and EVI1 Overexpression

Efficacy of Novel Non-Chemotherapy Combinations Against AML Cells with Mutant NPM1

Bruton's Tyrosine Kinase (BTK) Degrader Nx-2127 Exhibits Lethal Activity and Synergy with Venetoclax and BET Protein Inhibitor Against MCL Cells Sensitive or Resistant to Covalent BTK Inhibitors

Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53

Clinical-Stage Menin Inhibitor KO-539 Is Synergistically Active with Multiple Classes of Targeted Agents in KMT2A-r and NPM1-Mutant AML Models

Pre-Clinical Efficacy of Targeting TBL1/R-β-Catenin-TCF7L2 Axis Against AML with 3q26 Lesions and EVI1 Overexpression

Phase 1 Results of Novel Combination Therapy: BET Inhibitor PLX51107 with Azacitidine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Preclinically Effective Menin Inhibitor SNDX-50469 and SNDX-5613-Based Combinations Against MLL1-Rearranged (MLL-r) or NPM1-Mutant AML Models

Homoharringtonine and Mebendazole Are Preferentially Lethal Against Models of Myeloid Malignancy Associated with Germline Mutant RUNX1

Targeting Levels, Aberrant Localization or Oligomerization of Mutant Nucleophosmin Induces Differentiation and Loss of Survival of Human AML Cells with Mutant NPM1.

Synergistic Activity of Co-Treatment with PIM1 Kinase Inhibitor SGI-1776 and Histone Deacetylase Inhibitor Panobinostat or Heat Shock Protein 90 Inhibitor AUY922 against Human CML and Myeloproliferative Neoplasm (MPN) Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only